GARCIA GABRIELA,KUBASEK WILLIAM,MACBEATH GAVIN,MOYO VICTOR
申请号：
NZ61442712
公开号：
NZ614427A
申请日:
2012.03.12
申请国别(地区):
NZ
年份:
2015
代理人:
摘要：
Disclosed is the use of an antibody that inhibits heregulin binding to ErbB2/ErbB3 heterodimer for manufacture of a medicament for treating a malignant tumour in a human patient, wherein the patient has been treated for malignancy with an anti-estrogen therapy and has become resistant to such therapy, wherein the malignant tumour, by analysis of a tumour biopsy taken from the patent after the patient has become resistant, is estrogen receptor positive and expresses HER2, wherein the antibody inhibits heregulin-mediated activation of estrogen receptors in malignant tumour cells, which activation comprises phosphorylation of estrogen receptors, wherein the antibody is formulated for administration at a dosage that yields a concentration of the antibody in the patient&rsquo；s bloodstream that is a sufficient concentration to inhibit heregulin-induced estrogen receptor phosphorylation in MCF7 cells in vitro by at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, or at least 70%, and wherein the antibody comprises, VH CDR1, 2 and 3 sequences as shown in SEQ ID NOs: 3-5, respectively, and, VL CDR1, 2 and 3 sequences as shown in SEQ ID NOs: 6-8, respectively.
